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Abstract 
Background: Stilbenes, 1,2-diphenylethen derivatives, including resveratrol and combretastatins, show anticancer 
features especially against tumor angiogenesis. Fosbretabulin, CA-4, in combination with carboplatin, is in the last 
stages of clinical tests as an inhibitor of thyroid cancer. The mode of action of these compounds involves suppression 
of angiogenesis through interfering with tubulin (de)polymerization. 
Objective: We have previously synthesized five E-2-hydroxystilbenes and seven dibenzo[b,f]oxepins in Z 
configuration, with methyl or nitro groups at varied positions. The aim of the present work was to evaluate the 
anticancer activity and molecular mechanism(s) of action of these compounds. 
Results: Two healthy, EUFA30 and HEK293, and two cancerous, HeLa and U87, cell lines were treated with four 
newly synthetized stilbenes and seven oxepins. Two of these compounds, JJR5 and JJR6, showed the strongest 
cytotoxic effect against cancerous cells tested and these two were selected for further investigations. They induced 
apoptosis with sub-G1 or S cell cycle arrest and PARP cleavage, with no visible activation of caspases 3 and 7. 
Proteomic differential analysis of stilbene-treated cells led to the identification of proteins involved almost 
exclusively in cell cycle management, apoptosis, DNA repair, and stress response, e. g. oxidative stress. 
Conclusions: Among newly synthesized stilbene derivatives we selected two as potent anticancer compounds 
triggering late apoptosis/necrosis in cancerous cells through sub-G1 phase cell cycle arrest. They changed cyclin 
expression, induced DNA repair mechanisms, enzymes involved in apoptosis, and oxidative stress response. 
Compounds JJR5 and JJR6 can be a base for structure modification(s) to obtain even more active derivatives. 
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Introduction 
Cancer has become one of the most important health problems characterized by the high cost of treatment and 
uncertain prognosis. This situation forces searching for new anticancer agents, of natural origin or chemically 
synthetized, showing multi-targeting activity and no toxicity to normal cells. Most of the solid tumors develop their 
own vascular supply in the process of angiogenesis. Suppression of angiogenesis by vascular targeting agents 
(VTAs) becomes a promising approach. VTAs can be divided into two groups: (i) angiogenesis inhibitors (AIs) and 
(ii) vascular disrupting agents (VDAs). Stilbenes are natural 1,2-diphenylethen derivatives and include resveratrol 
(3,5,4’-trihydroxy-trans-stilbene), commonly found in grapes and red wine 1. It forms Z- or E-isomers, and/or 
glucosides (Z-/E-piceid). Unfortunately, after intake it is metabolized to glucuronide and sulfate conjugates lowering 
substantially its bioavailability 2. Combretastatins are the other class of stilbenes first isolated from the bark of the 
African willow tree (Combretum caffrum) that potentially fulfill conditions for being VTAs 3-5. The most extensively 
tested agent is combretastatin A-4 (CA-4). Binding to β-tubulin at the colchicine binding site, it inhibits tubulin 
polymerization disclosing highly anti-mitotic and anti-angiogenetic activities 4, but unfortunately showing low 
stability 6. In the more stable phosphorylated form, CA-4P, it inhibits gastric tumor metastasis and increases 
antitumor immune response 5. Upon administration, combretastatin A-1 diphosphate, CA-1P (OXi 4503), is 
dephosphorylated to CA-1 promoting microtubule depolarization, disruption of the tumor blood flow, and cell cycle 
arrest leading to apoptosis/necrosis. Additionally, it produces free quinone radicals creating reactive oxygen species 
7. Fosbretabulin, disodium phosphate derivative of CA-4, in combination with carboplatin, is in the last stages of 
clinical tests in patients suffering from thyroid cancer 8 (https://clinicaltrials.gov/ct2/home).  
Greene and co-workers (2012) tested CA-4 and its azetidinone Z-restricted analog, CA-432, against adenocarcinoma-
derived CT-26, Caco-2, and HT-29 and fibrosarcoma-derived HT-1080 cells 9. 
Combretastatin analogues, almost without exception, share a 3,4,5-trimethoxyaryl ring (A-ring) structure widely 
accepted as essential for biological activity. During our previous study, we developed the synthetic routes for 12 new 
derivatives of dibenzo[b,f]oxepin, including five Z-izomers of (E)-2-hydroxystilbenes and seven variously 
substituted dibenzo[b,f]oxepins with a Z-stilbene motif in their skeleton 10. 
The aim of the present work was to evaluate the anticancer activity and molecular mechanism of action of these 
compounds. Four cell lines: fibroblasts EUFA30 and human embryonic kidney HEK293, representing healthy 
tissues, and cervical cancer HeLa and glioblastoma U87, representing cancer cells, were subjected to four stilbenes 
and seven oxepin derivatives. Two of the stilbene derivatives, JJR5 and JJR6, showed relatively high activity against 
cancerous cells tested and were selected for further investigations. They induced apoptosis with sub-G1 or S cell 
cycle arrest, with no visible activation of caspases 3 and 7, but inducing PARP cleavage. Proteomic differential 
analysis led to the identification of several proteins involved in cell cycle management, cytoskeleton, and stress 
response, e.g. oxidative stress, like heme oxidase HO-1. We conclude that JJR5 and JJR6 compounds are worth 
further investigation and can be a base for structure modification(s) creating more active compounds. 
 
Material and Methods 
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Stilbenes and oxepins 
We have synthesized 12 derivatives of dibenzo[b,f]oxepines from substituted 2-hydroxy-2’,4’-dinitrostilbenes  as 
described in detail in Krawczyk et al. (2016) 10. 
Cell cultures and treatments 
Fibroblasts EUFA30 originated from the Department of Toxicogenetics, Leiden University Medical Centre, The 
Netherlands. Human embryonic kidney HEK293 cells (CRL-15730) were purchased from the American Type 
Culture Collection (ATCC). Cervical cancer HeLa (93021013) and glioblastoma U87 (89081402) cells were 
provided by the European Collection of Authenticated Cell Cultures (ECACC). Cells were cultured in DMEM 
medium (Thermo Fisher Scientific) supplement with 10% fetal bovine serum (Thermo Fisher Scientific), 0,1% 
antibiotics (penicillin, streptomycin, Thermo Fisher Scientific). Cells were grown in a humidified atmosphere of 5% 
CO2 in air at 37°C. 
Cytotoxicity assay 
Exponentially growing cells were seeded onto a 96-well plate at the density of 2 x 103 cells/well, cultured for 18 h, 
and the respective treatment (DMSO or tested stilbenoid in indicated concentration) was applied for 24 h or 48 h. 
Alamar Blue (Thermo Fisher Scientific) was added accordingly to manufacturer protocol. After 4 h, light emission at 
590 nm was measured with excitation at 560 nm using a scanning multiwell spectrophotometer Synergy HTI 
(Biotek). The experiment was carried out at least three times with three replicates for each inhibitor concentration. 
After background subtraction, inhibition rates IC50 were calculated. 
Flow cytometry 
The Annexin V-FITC apoptosis detection kit (BD Biosciences) was used to detect apoptosis by flow cytometry. 
Cells were seeded at 6-well plates at a concentration of 5 x 105 cells/well, cultured for 18 h, and tested agent was 
applied for indicated periods. Afterward, cells were washed with PBS, resuspended in binding buffer at a 
concentration of 2 x 106 cells/ml, and anti-Annexin V FITC-conjugated antibody and propidium iodide were added to 
100 µl aliquots. The mixtures were incubated for 15 min at room temperature, supplemented with binding buffer to 
500 µl and processed by BD FACSCalibur (BD Biosciences). Data were analyzed in Flowing Software version 2.5.1 
(Flowing Software, http://www.uskonaskel.fi/flowingsoftware). 
Western-blot analysis 
Total proteins were extracted from HEK293, Hela, and U87 cell with RIPA buffer (Sigma-Aldrich) in the presence 
of protease inhibitor cocktail (Sigma-Aldrich). Cellular debris were spun down and supernatant analyzed for protein 
content by Bradford assay (Bio-Rad). Samples were diluted with SDS-PAGE loading buffer to a final protein 
concentration of 2 μg/μl and 10 μl loaded on the Mini-PROTEAN TGX 4-15% gradient gel (Bio-Rad). The Western-
blot analysis was performed with the following antibodies used at 1:200 dilution: for monoclonal anti-ALKB (Santa 
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Cruz Biotechnology INC, sc-374301), monoclonal anti-ALKBH3 (Santa Cruz Biotechnology INC, sc-376520), 
monoclonal anti-FTO (Santa Cruz Biotechnology INC, sc-374301), monoclonal anti-ALKBH5 (Sigma–Aldrich, 
HPA007196), polyclonal anti-Caspase-3 (Cell Signaling, 9662), polyclonal anti-Caspase-7 (Cell Signaling, 9492), 
polyclonal anti-PARP (Cell Signaling, 9542), anti-tubulin (Santa Cruz Biotechnology INC, sc-58885), and anti-p53 
(Santa Cruz Biotechnology INC, sc-6243) antibodies. Appropriate secondary antibodies conjugated with horse-
radish peroxidase were used. Chemo-luminescence was measured using the ChemiDoc MP Imaging System (Bio-
Rad). Total protein was standardized in four steps: (i) equal amounts of cells were taken for extractions in RIPA 
buffer; (ii) the extract was then assayed by Bradford for protein content; (iii) equal amounts were loaded onto the gel 
and verified by Coomassie staining; (iv) proteins transferred to the nitrocellulose membrane were visualized by 
Ponceau-S reversible staining prior to the final Western-blot analysis. 
Proteomic analysis 
Samples were prepared as for the Western-blot analysis, loaded on the gradient gel, and after short run bands were 
cut out. Peptide mixtures were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS-
MS/MS) using the Nano-Acquity (Waters) LC system and the Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific). Prior to the analysis, proteins were subjected to the standard “in-gel digestion” with proteins reduced 
with 50 mM TCEP (60 min, 60°C), alkylated with 200 mM MMTS (45 min, room temperature) and digested 
overnight with trypsin (sequencing Grade Modified Trypsin, Promega). Peptide mixtures were applied to RP-18 
precolumn (nanoACQUITY Symmetry C18, Waters) using 0.1% TFA as a mobile phase and then transferred to 
nano-HPLC RP-18 column (nanoACQUITY BEH C18, Waters) using the acetonitrile gradient (5-35% acetonitrile, 
180 min) in the presence of 0.05% formic acid with the flow rate of 250 nl/min. Column outlet was directly coupled 
to the ion source of the spectrometer working in the regime of data dependent MS to MS/MS switch. A blank run 
ensuring lack of cross contamination from previous samples was included. Acquired raw data were processed by 
Mascot Distiller followed by Mascot Search (Matrix Science) against UniProt (v. 201604) database restricted to 
Homo sapiens sequences. Search parameters for precursor and product ions mass tolerance were 20 ppm and 0.1 Da, 
respectively, enzyme specificity: trypsin, missed cleavage sites allowed: 1, fixed modification of cysteine by 
methylthiol and variable modification of methionine oxidation. Peptides with Mascot Score exceeding the threshold 
value corresponding to < 5% expectation value and FDR < 1%, calculated by Mascot procedure were considered as 
positively identified. 
The mass calibration and data filtering described above were carried out with MScan software 
(http://proteom.ibb.waw.pl). Only proteins represented by at least two peptides were considered and proteins 
identified by a subset of peptides from another protein were excluded. Peptides lists that matched the acceptance 
criteria from the LC-MS/MS runs were merged and overlaid onto 2-D heat maps generated from the LC-MS/MS 
datasets, using m/z and retention times coordinates, validated by predicted and observed isotopic pattern correlation 
(acceptance criteria: RMS > 90%) using MSparky (http://proteom.ibb.waw.pl). Peptide intensities were determined 
as the surface of the isotopic envelope of the tagged isotopic envelopes. Finally, lists of identified peptides with 
corresponding quantitative values were exported for statistical analysis carried out with Diffprot software 11. Prior to 
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the analysis, quantitative values were normalized with LOWESS. Proteins with more than 90% common peptides 
were clustered and only peptides unique for the cluster were used for statistical analysis. Only proteins with q-values 
< 0.05 were taken into consideration during further analysis. 
Molecular modeling of /-tubulin interactions with selected stilbenes and Z-restricted analog  
The optimum ground-state geometry for compounds JJR5, JJR6, JJR9, and HKKJ8 were calculated using density 
functional theory (DFT) 12-13. The B3LYP functional and 6-311G 6-311++g (2d,p) basis set and the continuum model 
(PCM; Gaussian 03W) 13 were used in order to simulate the effects of the DMSO solvent. Molecular docking of 
compounds  into the 3D X-ray structure of tubulin (PDB ID: 1SA0)  was carried out using the Auto-Dock Vina 
software (the BFGS method) 14. Configurations of protein/dimethoxydibenzo[b,f]oxepin complex were created using 
UCSF Chimera software 15. The graphical user interface ADT was employed to set the enzyme, all hydrogens were 
added. For macromolecules, pdbqt files generated were saved. The 3D structures of ligand molecules were built, 
optimized (B3LYP functional and 6-311G 6-311++g (2d,p) basis set level), and saved in Mol2 format. The graphical 
user interface ADT was also employed to set up the ligand and the pdbqt file was saved. Auto-Dock Vina software 14 
was employed for all docking calculations. The AutoDockTools program was used to generate the docking input 
files. In docking, a grid box size of 44 x 46 x 44 points in x, y, and z directions was built, and the maps were center 
located (115.574, 89.495, 7.664) in the catalytic site of the protein. A grid spacing of 0.375 Å (approximately 1/4 of 
the length of carbon-carbon covalent bond) was used for the calculation of the energetic map. 
Statistical analysis 
Statistical analyses were done using Origin 2015 software (OriginLab Corporation). For cytotoxicity curves, non-
linear fit was used with logistic dose response model implemented in OriginPro. 
Results and Discussion 
Cytotoxic effect of stilbenes and oxepins tested towards cancerous cells 
In the present study we evaluated the cytotoxic efficacy of previously synthetized four stilbene and seven oxepin 
derivatives on two cancerous (HeLa and U87), and two healthy (EUFA30 and HEK293) cell lines (Fig. 2). The 
compounds JJR1, JJR5, JJR6, and JJR9 and HKKJ8, JJR1-2, JJR2-2, JJR5-2, JJR6-2, JJR7-2, and JJR9-2 have E and 
Z configuration, respectively. Stilbene/oxepin-mediated growth inhibition proceeded in a dose-dependent manner 
and the effect was stronger for HeLa than U87 cells. Generally, stilbenes were more cytotoxic than oxepins, and all 
of them were more toxic to cancerous than healthy cells. For active compounds, IC50 values were the lowest after 48 
h of HeLa treatment for four stilbenes, JJR1, JJR5, JJR6, and JJR9, and one oxepin, HKKJ8, and amounted 3.50, 
17.18, 6.97, 17.05, and 18.54 M, respectively. The JJR5 stilbene was the most effective against U87 cells with IC50 
of 48.93 µM after 48 h of treatment (Table 1). Similar results were obtained with proliferation assay based on BrdU 
incorporation (data not shown). 
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Table 1. IC50 values (M) of tested stilbene and oxepin derivatives based on the survival of EUFA30, HeLa, and 
U87 cells after 48 h of treatment. 
Stilbene/oxepin: 
Cells type: 
EUFA30 HeLa U87 
JJR1 - 3.50 - 
JJR5 52.08 17.18 48.93 
JJR6 42.72 6.97 55.76 
JJR9 - 17.05 - 
HKKJ8 - 18.54 54.07 
JJR6-2 - 54.82 - 
JJR7-2 - 43.39 - 
 
To summarize, the anticancer activity is developed by substitution of methoxy group in various positions of 2-
hydroxy-2’,4’-dinitrostilbene skeleton. The most active against HeLa and U87 cells were the stilbenes with a 
methoxy (or nitro) group in positions 3, 4, and 5; however, the presence of a substituent in positon 6 renders it 
inactive. The substituted ring due to electron donating (EDG) hydroxyl group has enriched electron density. 
It should be also considered that for some compounds, e.g. JJR1 tested against HeLa cells, the cytotoxic effect 
depended upon the time of treatment. After 24 h, this stilbene was the least effective, but after 48 h it reached the 
lowest among stilbenes tested IC50 value of 3.50 M.  
CA-4/benzoxazolone hybrids were checked against HepG2, EA.hy 962, and K562 cells. One of them reached IC50 
value in the range of 50-750 nM. When tested against relatively resistant cancer cells, this derivative was more toxic 
than CA-4, e.g. the IC50 reached 0.25 µM for colorectal adenocarcinoma HT-29 cells compared to 2.62 µM for CA-4 
after 72 h of treatment. A similar phenomenon was observed for mouse colon carcinoma Colon-26 and human 
adenocarcinomic alveolar basal epithelial A-549 cells. Also, the E-isomers were studied but did not show the activity 
below the concentration of 50 µM 16. 
CA-4 and CA-432 were very active against HT1080 and CT-26 cells showing IC50 values below 10 nM. Caco-2 cells 
survived at about 10-fold better rate. In the case of these three cell lines, stabilization of Z conformation slightly 
lowered the activity of the latter. Although both compounds were less active against HT-29 cells, with IC50 value for 
CA-4 equal to about 10 M, its CA-432 derivative acted 10-fold stronger 9 indicating that the ethylene bridge 
influences anti-cancer activity of stilbene depending on the cell type tested. 
Taking under consideration high cytotoxicity against cancerous and low effect on healthy cells, for further tests 
stilbenes JJR5, JJR6, and JJR9 and oxepins HKKJ8, JJR5-2, JJR6-2, and JJR9-2 were selected. 
Effect of stilbenes and oxepins derivatives on the induction of apoptosis 
To measure apoptosis induction, cells were treated for 24 and 48 h with 50 or 100 M JJR5 or JJR6 (Fig. 3, 
Supplementary Fig. S1). The HEK293 cells were the least sensitive showing only a slight increase in necrotic (PI+) 
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and late apoptotic (Annexin-FITC+PI+) cells, namely, 18.4% and 17.5% comparing to 1.3% and 8.2% in control 
cells. The HeLa cells were the most sensitive to both JJR5 and JJR6. After 24 h of JJR5 treatment, 40.1% of cells 
were in early apoptosis (Annexin-FITC+), transforming almost entirely, 85.2%, into late apoptosis after 48 h. JJR6 
was less active than JJR5 against HeLa cells producing 42.8% in early, and 41.3% in late apoptotic cells after 48 h. 
Both compounds were more effective than camptothecin used as a control. U87 cells were the most resistant to 
stilbenes tested. JJR5 was more active than JJR6, increasing the number of early and late apoptotic cells to 28.4% 
and 47.2% comparing to 3.8% and 9.6% in control cells, and necrotic cells from 2.2% to 8.5%. On the contrary, JJR6 
caused slight increase in early and late apoptosis, to 8,2% and 18.6%, respectively (Fig. 3). 
A typical apoptotic pathway employs activation of p53 protein and caspases. The activation of caspases 3 and 7 
depends on the proteolytic cut of procaspases into p17 and p20 units, respectively. During apoptosis also PARP 
(p116), a protein involved in DNA repair, is inactivated by the cleavage producing p89 unit. 
Consistently with previous results (the lack of significant changes in apoptosis induction), the Western blot analysis 
did not show the cleavage of PARP protein by JJR5, JJR6, and HKKJ8 compounds in HEK293 and U87 cells, with 
the exception of HKKJ8-treated HEK293 cells. However, the PARP cleavage product appeared in HeLa cells treated 
with the same derivatives. HKKJ8 induced proteolysis of PARP also in HEK293 cells (Fig. 4). Additionally, the 
slight induction of p53 in all cell lines can be observed after the addition of JJR5 and JJR6 (Fig. 4). We did not 
observe the activation of caspases 3 and 7. Results obtained suggest that the possible way of action of stilbenes could 
be the induction of necrosis rather than apoptosis. Additionally, these effects resemble the action of doxorubicin on 
human kidney proximal tubular HK-2 cells causing cell death through the p53 independent pathway inducing PARP 
cleavage to p55 subunit and only slightly increasing the caspase 3 activity 17. 
In MCF-7 cells, the 250 M resveratrol induced apoptosis at 30% after 48 h, with only slight activation of caspase 9 
and no visible detection of caspase 3 18. In these cells the possible apoptosis pathway is lead by calpain activation 19. 
Also Sawai and Domae (2011) have indicated that primary necrotic and post-apoptotic secondary necrotic cells 
cannot be distinguished by Annexin/PI staining and that primary necrotic cells are Annexin-FITC+PI– before they 
become PI+ 20. The AIF-dependent and caspase-independent pathway of apoptosis could not be excluded 21. 
The routes leading to apoptosis, among others, depend on cell type used for testing. Apoptosis has been induced in 
p53-positive human liver cancer Hep G2 cells through p53 pathway with elevated expression of p21 and Bax but not 
Fas/APO-1 22. On the contrary, when used with As2O3, resveratrol induced the expression of Fas and FasL, 
cytochrome C leakage, and oxidative stress leading to caspase-independent apoptosis 23. Additionally, in human 
epidermoid carcinoma A432 cells, it activated apoptosis through pRb-E2F/DP pathway 24. 
Significantly, CA-4 and CA-432 have induced different apoptotic/death pathways depending on the cells treated. In 
fibrosarcoma HT-1080 cells, caspase-dependent apoptosis has been triggered. In contrast, adenocarcinoma CT-26 
cells have increased in size and contained multiple nuclei and vacuoles, and translucent cytoplasm resembling 
necrosis. On the other hand, the survival of HT-29 (p53-positive) cells can be, at least partially, explained by 
autophagy. Moreover, the prolonged exposure to both combretastatins led to the formation of the acidic vesicular 
organelles (AVOs) in 45-50% of polyploid, non-apoptotic/non-necrotic cells. A similar effect has been observed in 
HT-29 and Caco-2 cells. On the contrary, HT-1080 cells have not been changed 9. 
9 
 
Cell cycle distribution 
Cell cycle distribution was tested using JJR5 and JJR6 stilbene derivatives. After 24 h of JJR5 treatment, HEK293 
cells did not show any significant changes, with slight increase in sub-G1 population: 11.9% versus 7.7% in control 
cells (Fig. 5 and Supplementary Fig. S2). The sub-G1 population in HeLa cells was much more significant reaching 
18.8% and 11.4% in cells treated with JJR5 and JJR6, respectively, in comparison to 5.6% in control. The U87 cells 
behaved differently showing greater sub-G1 and S phases cell populations, 8.9% and 21.4% compared to 3.3 and 
16.1% in control cells treated with JJR5. JJR6 treatment increased cells in S phase to 29.3% not changing the sub-G1 
population. Surprisingly, in U87 cells treated with either JJR5 or JJR6, the number of cells showing polyploidy 
raised significantly, from 2.8% in control to 12.7% and 11.9%, respectively. On the contrary, HeLa cells showed 
only slight increase in polyploidy, 6.5% and 7.8% in JJR5 and JJR6 treated cells, compared to 4.4% in the control. 
To sum up, it should be noted that tested stilbenes direct the cells to sub-G1 phase indicating cell death, and in the 
case of U87, stuck the cells in S phase with a more significant effect of JJR6 than JJR5. Additionally, U87, the most 
resistant among cells tested, could escape apoptosis/necrosis through polyploidy. 
The CA-4 retarded HepG2 cells at mitosis 25 by 6% lower than its benzoxazolone derivative, increasing the cell 
population in G2/M phase from 28 to 39% after 8 h treatment. Both compounds reached the retardation maximum at 
24 h of treatment (about 80%) followed by sub-G1 enrichment “directly from mitotic arrest”. Some cells escaped the 
cell cycle arrest and underwent cell divisions increasing their DNA content to more than 4N 16 which is consistent 
with our results. 
Resveratrol has exerted G2/M cell cycle retardation in oral squamous carcinoma cells by cyclins A2 and B1 26. On 
the other hand, resveratrol is also capable to arrest cells at G1 phase as it has been observed in human epidermoid 
carcinoma A431 cells. The mechanism of action involves induction of Cdk1, and the reduction of cyclins D1, D2, 
and E and Cdk2, Cdk4, and Cdk6 27. Similar phenomenon has been shown for liver carcinoma cells 22. Treated with 
resveratrol metabolites, colon cancer cells have been inhibited at G1/S phase with the depletion of cyclin D1 through 
A3 adenosine receptor 28. Also, the retardation in S phase and apoptosis has been observed for treated with 
resveratrol anaplastic thyroid carcinoma cells 29. In CT-26 and HT-1080 cells, 8 h treatment with 50 nM CA-4 
caused cell cycle arrest at G2/M phase of more than 50% of cells. Treatment of CT-26 cells prolonged to 48 h, has 
increased sub-G1 population by 20% and polyploidy by 35%. In HT-1080 cells, only sub-G1 has soared to about 
50%. Caco-2 cells were induced to cell death (about 15%) as well as to polyploidy (about 30%). In HT-29 only cell 
death has been induced 9. After 48 h of 25 M resveratrol treatment, the A549 cells have been arrested in G1 phase 
at 70% (compared to 50% in control). This was connected with the altered expression of cyclins A, B, and D3 and 
Chk1, Cdk1, CDC27, Eg5, integrins, and ASS 30. 
Proteomic analysis 
The proteomic differential analysis allowed to identify four to 18 proteins that either appeared only in control/treated 
cells or of which q-values were at the level of < 0.11 in cells treated with JJR5 and JJR6 derivatives (Supplementary 
Tables S1-S6). The significance of several of these proteins is described below. 
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Tested compounds influenced the oxidative stress response by upregulating e.g. the glutathione S-transferase Mu 3 
(Supplementary Table S1), heme oxidase-1 HO-1 or thioredoxin reductase 1 (Tables S5 and S6) in U87 cells. These 
findings are consistent with the results of other groups. Resveratrol promoted antioxidant microenvironment by the 
regulation of SOD, CAT, glutathione reductase, peroxidase, and transferase, as well as GSH and other antioxidants, 
thus decreasing damage to DNA in the rat model of colon carcinogenesis 31. On the contrary, resveratrol derivative, 
the 3,3’,4,4’-tetrahydroxy-E-stilbene, has induced the production of ROS increasing activity of antioxidant cell 
machinery consequently decreasing DNA lesion 8-oxo-guanine and senescence-associated β-galactosidase in human 
peritoneal mesothelial cells 32. It was established that resveratrol has induced the expression of heme oxidase HO-1 
and glutamate-cysteine ligase GCLC via Akt/protein kinase B and extracellular signal-regulated protein kinase 
ERK1/2 and Nrf2 transcription factor in PC12 cells 33. High throughput Western blot screening of A549 cells treated 
with 25 M resveratrol for 48 h showed changes of more than 1.25-fold for 127 proteins. Surprisingly, HO-1 protein 
and caspase 2 were found to be down-regulated. Based on microarray experiments, the authors also found 157 genes 
of expression altered more than 2-fold. The pathways changed by resveratrol included: G1-S and G2-M checkpoints, 
apoptosis cascade as well as TGF-b, NF-kB, and MAPK/JNK pathways 30. 
Parafibromin is a tumor suppressor found only in untreated HEK293 cells (Supplementary Tables S1 and S2). It 
influences the  cell cycle through the inhibition of cyclin D1/PRAD1 expression 34. Additionally, in HEK293 cells, 
JJR5 induced cullin-5 CUL5 protein, a substantial part of SCF-like ECS (Elongin-Cullin 2/5-SOCS-box protein) E3 
ubiquitin-protein ligase complex probably ubiquitinating JAK2 kinase, arresting cell cycle progression (via 
homology to CUL1), and inducing apoptosis by constituting vasopresin cell surface receptor 35. In cells treated with 
JJR5 or JJR6, we also identified the change in the expression of G2/M-specific cyclin B1 (Supplementary Table S2) 
and other cyclins (although with no statistical significance), being in agreement with the modulation of cell cycle 
phases. Another protein connected with cell cycle is Ran-specific GTPase-activating protein RANBP1 
(Supplementary Table S6). 
The substantial part of differentially identified proteins constitute these connected to DNA/RNA metabolism and 
repair. This proteins include down-regulated ATP-dependent RNA helicase DDX54 (Supplementary Table S2), UV 
excision repair protein RAD23 homolog B appearing only in treated HeLa cells (Supplementary Tables S3 and S4), 
or down-regulated DNA replication licensing factor MCM3 (Supplementary Table S5). Resveratrol and its 
metabolites have inhibited TOPO2 through histone H2AX phosphorylation causing TOPO-DNA permanent complex 
in glioblastoma cells inducing DNA damage 36-37, and in breast and colon cancer cells accompanied by decreased 
nuclear TERT 38. The study conducted on MCF-7 cells treated with resveratrol showed the substantial inhibition of 
mismatch repair (MR), DNA replication, homologous recombination (HR), e.g. MRN complex, and cell cycle 
pathways 39. In cells treated for 48 h with 250 M resveratrol, the proteomic analysis revealed seven differentially 
appearing proteins: down-regulated HSP27, translationally controlled tumor protein TPT1, peroxiredoxin 6, stress-
induced-phosphoprotein 1 STIP1, pyridoxine-5’-phosphate oxidase 1 PNPO, and hypoxantine-guanine 
phosphoribosyl transferase HGPRT1, and one up-regulated triosephosphate isomerase TPI1 18. 
Among proteins connected with RNA metabolism they were: (i) found only in JJR5-treated HEK293 cells nuclear 
RNA export factor 1 (Supplementary Table S1); (ii) present only in control HEK293 cells ribosomal RNA small 
11 
 
subunit methyltransferase NEP1 (Supplementary Table S1); (iii) increased by JJR6-treatment in HeLa tyrosine-
tRNA ligase (Supplementary Table S4); (iv) increased by JJR5-treatment in U87 glycine-tRNA ligase 
(Supplementary Table S5); (v) RNA-binding protein involved in modulation of mRNA transcription by Polymerase 
II (Q9Y224) (Supplementary Table S5). These findings clearly indicate that RNA/protein metabolism is modulated 
by stilbene derivatives tested. 
Separate group of proteins takes part in ubiquitin metabolism, namely, ubiquitin-like protein ISG15 (Supplementary 
Table S4) and ubiquitin-conjugating enzyme E2 N UBE2N (Supplementary Table S6). This is in agreement with the 
proteomic analysis of cerebral cortex of rats treated with resveratrol in middle cerebral artery stroke model where 29 
proteins were identified with more than 2.5-fold change. These group of proteins included peroxiredoxin-5, ubiquitin 
carboxy terminal hydrolase L1 UCH-L1, isocitrate dehydrogenase NAD+ subunit , apolipoprotein A-I, collapsing 
response mediator protein CRMP-2, mitogen activated protein MAP kinase 1, and nucleoside diphosphate kinase B 
indicating that this stilbene influences pathways connected with oxidative stress, energy metabolism, and signaling 
40. 
An important finding is the change of the presence of -glutamylcyclotransferase (Supplementary Tables S1 and S2) 
present only in treated HEK293 cells. The protein is responsible for the induction of cytochrome C release from 
mitochondria, thus triggering apoptosis 41. Treated with stilbene HeLa cells (Supplementary Tables S3 and S4) 
exhibited induction of (i) Annexin A2, the protein involved in apoptosis 42 but normally promoting actin 
polymerization 43, and (ii) anamorsin CIAPIN1 acting as a factor inhibiting cell death by cytokine regulation 44. 
Interestingly, in HEK293 cells, JJR6 suppressed the G-rich sequence factor 1 GRSF1 responsible for the assembly of 
mitochondrial ribosomes and recruitment of ND6 mRNA and cytb and ND5 lncRNAs 45. 
Stilbenes/oxepins activity against ALKBH dioxygenases 
ALKBH proteins are members of the dioxygenase family present in almost all organisms first discovered in bacteria 
as a protection system against methylating damage to DNA. There are nine AlkB homologues in humans (ALKBH1-
8 and FTO) showing activity against variety of substrates including reversible methyl modifications in RNA. We 
have found the expression of selected ALKBHs in cancer cells that implies involvement of these dioxygenases in 
cancer DNA/RNA metabolism. Thus, we evaluated the influence of stilbenes/oxepins on the expression of these 
proteins. With the use of Western blot analysis we found no such activity of compounds tested (data not shown). 
Molecular modeling studies to determine the probability of /-tubulin interactions with selected stilbenes 
and Z-restricted analog 
Microtubules are dynamic polymers with an /-tubulin heterodimer as the essential structural element. The tubulin 
heterodimer contains at least three distinct drug binding sites: the paclitaxel, vinblastine, and colchicine sites 46. Up 
to now, no colchicine site inhibitor useful in anticancer therapy has been found. The derivatives of stilbene interact 
with the colchicine binding site of /-tubulin heterodimer. We conducted a computational docking experiment to 
identify possible /-tubulin interactions with JJR5, JJR6, and JJR9 stilbenes and dibenzo[b,f]oxepin HKKJ8 – the 
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analog incorporating Z-stilbene scaffold. Compounds were generated using molecular modeling software 14-15 and 
docked into the /-tubulin (PDB ID: 1SA0) .  
The interaction of JJR5, JJR6, or HKKJ8 at colchicine binding site can be observed. On the other hand, JJR9 appears 
at another site (Fig. 6). In the binding mode, JJR5, JJR6, or HKKJ8 binds to the colchicine binding site of tubulin via 
hydrophobic interactions stabilized by a hydrogen bond. The calculated binding energies were used as the parameters 
for the selection of the cluster of docking posed to be evaluated (Fig. 6a-c). The selected structures of JJR5, JJR6, 
JJR9, and HKKJ8 have the estimated binding free energy of -7.0, -7.3, -7.7, and 7.4 kcal/mol, respectively, whereas 
the binding free energy of colchicine and CA-4 are -8.6 and -7.6 kcal/mol, respectively 47. The models are similar to 
that for colchicine/CA-4 at the colchicine binding site. The compounds JJR5, JJR6, and HKKJ8 were embedded in 
the hydrophobic pocket occupied by the A ring of colchicine (Fig. 6a-d). Overall, these results suggest that the new 
derivatives interact strongly with tubulin, similarly to colchicine and CA-4. 
Conclusions 
We tested 11 new stilbene derivatives against healthy EUFA30 and HEK293 and cancerous HeLa and U87 cells and 
elucidated the mode of action of two of them. The JJR5 and JJR6 were selected as the most potent compounds 
minimally affecting healthy EUFA30 cells. They triggered late apoptosis/necrosis in cancerous cells through sub-G1 
and/or S phase cycle arrest. The cell death seems to be caspase-independent indicating the caspase-independent 
apoptosis or regulated necrosis pathway. Besides changing the expression of cell cycle connected proteins like 
cyclins, the JJR5 and JJR6 compounds induced DNA repair mechanisms (UV excision repair protein RAD23 
homolog B), especially homologous recombination (HR) and enzymes involved in apoptosis through mitochondrial 
cytochrome C leakage (-glutamylcyclotransferase) and oxidative stress response (heme oxidase HO-1). 
The stilbenes tested are a good basis for further investigation, e.g. in the area of combinatorial therapy. 
Combretastatins together with paclitaxel are also toxic to the outer layers of solid tumors 48. The synergistic action 
could be potentiated directly in organisms by the fact that e.g. resveratrol acts as an inhibitor of cytochromes P450 
CYP1A1 or CYP3A4 thus potentially blocking the conversion of xenobiotics to carcinogens 49. 
Also there is a possibility of the modulation of other regulatory molecules like lncRNAs. A recent report has shown 
that resveratrol at the concentration of 25 M is able to change the expression of 40 lncRNAs, particularly 
AK001796, in lung cancer A549 cells 50. Similarly, our results imply the involvement of JJR5 and JJR6 compounds 
in the regulation of lncRNAs. 
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Figures description 
Figure 1. The structure of CA1P, CA4P and their sodium salts, OXi4503 and fosbretabulin, alongside of resveratrol 
and colchicine. 
Figure 2. The cytotoxic effect of A) stilbene (JJR1, JJR5, JJR6, and JJR9) and B) oxepin (HKKJ8, JJR1-2, JJR2-2, 
JJR5-2, JJR6-2, JJRJR7-2, and JJR9-2) derivatives on healthy EUFA30 and cancerous HeLa and U87 cells based on 
AlamarBlue assay, after 24 and 48 h of treatment. Non-linear fitting with logistic dose response model was employed 
and IC50 vales calculated if possible (see Table 1). 
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Figure 3. The distribution of HEK293, HeLa, or U87 cells stained with Annexin-FITC and propidium iodide (PI) 
after flow cytometry analysis. Cells were treated with 50 or 100 M JJR5 or JJR6 for 24 or 48 h. Camptothecin (10 
M) and H2O2 (1 mM) were used as experimental controls. Tested samples were prepared and analysed in 
duplicates. 
Figure 4. The Western-blot analysis of PARP, p53, and cytochrome C in HEK293, HeLa, or U87 cells treated with 
JJR5, JJR6, JJR9, HKKJ8, JJR5-2, JJR6-2, or JJR9-2 for 24 h. 
Figure 5. Cell cycle distribution in HEK293, HeLa, or U87 cells treated with 50 M JJR5 or JJR6 for 24 h. Tested 
samples were prepared and analysed in duplicates. 
Figure 6. 3D model of the interactions between compounds a) HKKJ8, b) JJR5, c) JJR6 and the colchicine binding 
site of a / tubulin d) JJR9 the other site of a / tubulin (crystal structure from PDB code: 1SA0). 
 
Supplementary Figures and Tables 
Figure S1. Dot plots of distribution of healthy, apoptotic, and necrotic cells based on Annexin-FITC and propidium 
iodide (PI) staining of HEK293, HeLa, or U87 cells treated with 50 M JJR5 or JJR6 for 24 h, an example. 
Figure S2. Histograms of cell cycle distribution in HEK293, HeLa, or U87 cells treated with 50 M JJR5 or JJR6 
for 24 h, an example. 
Table S1. Proteins identified in Differential Proteomic analysis of HEK293 cells treated with JJR5. 
Table S2. Proteins identified in Differential Proteomic analysis of HEK293 cells treated with JJR6. 
Table S3. Proteins identified in Differential Proteomic analysis of HeLa cells treated with JJR5. 
Table S4. Proteins identified in Differential Proteomic analysis of HeLa cells treated with JJR6. 
Table S5. Proteins identified in Differential Proteomic analysis of U87 cells treated with JJR5. 
Table S6. Proteins identified in Differential Proteomic analysis of U87 cells treated with JJR6. 
